Payment overview · 2025
General Payments
$175.95
9 reported records · 6 companies
Healthcare provider profile · identity verified
John Patrick Mcgee, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREENVILLE, NC · NPI 1194104091
Verified facts
What the public records show
CMS Open Payments records show John Patrick Mcgee, M.D. received $175.95 in general payments during 2025 across 9 reported records.
Exact Sciences Corporation accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.45 | 26.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.44 | 26.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.29 | 16.6% | 1 | 2025 |
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $19.36 | 11.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $19.10 | 10.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.31 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $175.95 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.45 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.44 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 437 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 120 |
| Losartan Potassium | Losartan Potassium | 309 | 81 |
| Gabapentin | Gabapentin | 248 | 74 |
| Omeprazole | Omeprazole | 247 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 42 |
| Furosemide | Furosemide | 152 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 45 |
| Lisinopril | Lisinopril | 146 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 42 |
| Famotidine | Famotidine | 133 | 43 |
| Eliquis | Apixaban | 121 | 31 |
| Metformin Hcl | Metformin Hcl | 121 | 35 |
| Pregabalin | Pregabalin | 121 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 31 |
| Tramadol Hcl | Tramadol Hcl | 115 | 25 |
| Metformin Hcl Er | Metformin Hcl | 110 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 109 | 34 |
| Simvastatin | Simvastatin | 103 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 35 |
| Carvedilol | Carvedilol | 95 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 41 |
| Ozempic | Semaglutide | 93 | 12 |
| Allopurinol | Allopurinol | 91 | 20 |
| Potassium Chloride | Potassium Chloride | 87 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 42 |
| Trazodone Hcl | Trazodone Hcl | 85 | 26 |
| Prednisone | Prednisone | 82 | 47 |
| Ezetimibe | Ezetimibe | 76 | 23 |
| Spironolactone | Spironolactone | 73 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 20 |
| Alprazolam | Alprazolam | 64 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 17 |
| Jardiance | Empagliflozin | 59 | 17 |
| Atenolol | Atenolol | 58 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 15 |
| Montelukast Sodium | Montelukast Sodium | 57 | 18 |
| Sertraline Hcl | Sertraline Hcl | 57 | 16 |
| Lorazepam | Lorazepam | 51 | 11 |
| Meloxicam | Meloxicam | 51 | 18 |
| Bupropion Xl | Bupropion Hcl | 50 | 12 |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 50 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Celecoxib | Celecoxib | 48 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 13 |
| Meclizine Hcl | Meclizine Hcl | 47 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Mirtazapine | Mirtazapine | 43 | 11 |
| Clonazepam | Clonazepam | 41 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 12 |
| Valsartan | Valsartan | 41 | 14 |
| Warfarin Sodium | Warfarin Sodium | 38 | 11 |
| Nystatin | Nystatin | 37 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 14 |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Glimepiride | Glimepiride | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 21 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 18 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 12 |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Bumetanide | Bumetanide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $175.95 · 9 records | Exact Sciences Corporation | Cologuard Collection Kit, FREESTYLE LIBRE 3, Flexitouch Plus, Freelite, INTELLIS ADAPTIVESTIM, Nimbl, WaveWriter Alpha Prime 16 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error